First Quarter 2020 12 May 2020 Dr. Andreas Eckert CEO 1 Globally - - PowerPoint PPT Presentation

▶
first quarter 2020 12 may 2020 dr andreas eckert ceo 1
SMART_READER_LITE
LIVE PREVIEW

First Quarter 2020 12 May 2020 Dr. Andreas Eckert CEO 1 Globally - - PowerPoint PPT Presentation

Apr 24, 2023 169 likes •419 views

First Quarter 2020 12 May 2020 Dr. Andreas Eckert CEO 1 Globally Globa lly Pos Positi itione oned Niche Play Niche Player er in I in Iso sotope tope Market Market ISOTOPE PRODUCTS MEDICAL * (industrial components) Radiation

slide-1
SLIDE 1

1

First Quarter 2020

12 May 2020

  • Dr. Andreas Eckert

CEO

slide-2
SLIDE 2

2

MEDICAL * Radiation Therapy Radiopharma Lab Devices

Globa Globally lly Pos Positi itione

  • ned

Niche Niche Play Player er in I in Iso sotope tope Market Market

ISOTOPE PRODUCTS

(industrial components)

Products Services Trade Disposal

45 Mio. EUR Revenues in Q1-2020

23 Mio. EUR 52%* 21 Mio. EUR 46%*

Slides only for illustration – the spoken word shall be binding

Engineering

*Since January 1, 2020, Eckert & Ziegler has consolidated its Radiation Therapy and Radiopharma segments under the new name MEDICAL

*figures without Holding segment

slide-3
SLIDE 3

>800 >800 Employ Employee ees (Head (Headco coun unts ts) ) 18 18 Site Sites s Wo World rldwide wide

3

Results Q1-2020

(Mio. EUR)

Revenues 44,5 Net Income 5,1

Slides only for illustration – the spoken word shall be binding

49% 41% 8% 2%

EUROPE AMERICA ASIA MIDDLE EAST & AFRICA

slide-4
SLIDE 4

Rev Reven enue ue Gro Growth wth

4 Slides only for illustration – the spoken word shall be binding

Q1-2020 Total Revenues 44,5 mm. EUR Q1-2019 Total Revenues 43,3 mm. EUR

  • incl. discontinued and continued operations
  • 5,00

10,00 15,00 20,00 25,00 30,00 Isotope Products Medical Q1-2019 27,0 16,4 Q1-2020 23,2 20,6 In mm. EUR

Growth over last year: +2%

slide-5
SLIDE 5

Isot Isotop

  • pe Pro

e Produ duct cts: s: Rev Reven enue ue Gro Growth wth Q1 Q1-20 2020 20, , in mm. in mm. EUR EUR

5 Slides only for illustration – the spoken word shall be binding

27,0

  • 4,5

+ 0,8 23,2

20 21 22 23 24 25 26 27 28 Revenues Q1-2019 Organic Growtth Exchange Rate Effects Revenues Q1-2020

slide-6
SLIDE 6

Med Medical: ical: Rev Reven enue ue Gro Growth wth Q1 Q1-20 2020 20, , in mm. in mm. EUR EUR

6 Slides only for illustration – the spoken word shall be binding

16,4 + 3,8 + 0,4 20,6

5 7 9 11 13 15 17 19 21 Revenues Q1-2019 Organic Growtth Exchange Rate Effects Revenues Q1-2020

slide-7
SLIDE 7

Net Net Rev Revenu enues es Growth Growth all Segmen all Segments ts in in Q1 Q1-202 2020, 0, in mm. in mm. EUR EUR

7 Slides only for illustration – the spoken word shall be binding

43,3

  • 3,7

+ 4,4 44,5

5 10 15 20 25 30 35 40 45 Revenues Q1-2019 Isotope Products Medical Revenues Q1-2020

slide-8
SLIDE 8

8 Slides only for illustration – the spoken word shall be binding

Ne Net Inc t Incom

  • me

e – Dist Distrib ribut ution ion an and Gr d Growth wth Q1 Q1-2020 2020

slide-9
SLIDE 9

Net Net I Inc ncome

  • me Gro

Growth wth

9

Q1-2020 Total Net Income 5,1 mm. EUR Q1-2019 Total Net Income 5,8 mm. EUR

Slides only for illustration – the spoken word shall be binding

0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 Isotope Products Medical Q1-2019 3,0 2,7 Q1-2020 1,4 3,5 In mm. EUR

Lost over last year: -13%

slide-10
SLIDE 10

Net Net I Inc ncome

  • me Gro

Growth wth all all Seg Segmen ments ts in Q1 in Q1-20 2020 20, , in mm. in mm. EUR EUR

10 Slides only for illustration – the spoken word shall be binding

5,8

  • 1,6

+ 0,8 + 0,0 5,1

0,0 1,0 2,0 3,0 4,0 5,0 6,0 7,0 Net income Q1-2019 Isotope Products Medical Holding Net income Q1-2020

slide-11
SLIDE 11

Isot Isotop

  • pe Pro

e Produ duct cts: s: Net Net Inco Income me Gro Growth wth Q1 Q1-20 2020 20, , in mm. in mm. EUR EUR

11 Slides only for illustration – the spoken word shall be binding

3,0

  • 1,1
  • 1,0

+ 0,5 1,4

1 1 2 2 3 3 Net income Q1-2019 Organic Growth Exchange Rate Effects Tax/Interest/Minorities Net income Q1-2020

slide-12
SLIDE 12

Med Medical: ical: Net Net Inco Income me Gro Growth wth Q1 Q1-20 2020 20, , in in mm.

  • mm. EUR

EUR

12 Slides only for illustration – the spoken word shall be binding

+ 2,7 + 4,2 + 2,1 + 0,5

  • 0,9

+ 3,5

1 2 3 4 5 6 7 Net income Q1-2019 Revenues COGS Sales and Administrative Cost Exchange Rate/Interesrt/Tax Net income Q1-2020

slide-13
SLIDE 13

13 Slides only for illustration – the spoken word shall be binding

Cas Cashflo hflow and w and Balan Balance ce She Sheet et Q1 Q1-2020 2020

slide-14
SLIDE 14

Balan Balance ce She Sheet et as as of

  • f 31

31/03/2 /03/202 020, 0, in in mm.

  • mm. EUR

EUR

14

  • Cash at Hand 81 mm. EUR
  • Debt Free
  • Equity Ratio 53% (+ 2% over Dec. 2019)

Slides only for illustration – the spoken word shall be binding

Cash 81 Equity 144 Recievables 29 Minority Interests 1 Inventory 33 IFRS 16 Leasing 19 Intangible Assets 52 Accruals/Provisions 68 Fixed Assets 40 Other Short Term Payables 37 Others 22 Other Long Term Payables 7 Total Activ 275 Total Passiv 275

slide-15
SLIDE 15

Net Net Liquidity Liquidity Q1 Q1-20 2020 20, , in in mm.

  • mm. EUR

EUR

15

+10 mm EUR Share Buy-Back

Folie nur zur Illustration – es gilt das gesprochene Wort

2014 2015 2016 2017 2018 2019 Q1-2020 Zahlungsmittel 22 31 37 58 54 79 81 Darlehen 19 16 12 2 Nettoliquidität 3 15 25 56 54 79 81 10 20 30 40 50 60 70 80 10 20 30 40 50 60 70 80 In mm. EUR

slide-16
SLIDE 16

Cas Cashflow hflow Q1 Q1-20 2020 20, , in in mm.

  • mm. EUR

EUR

16 Slides only for illustration – the spoken word shall be binding

EBITDA: 11,3 mm. EUR

78,9 4,7

  • 1,6
  • 1,2

0,1 80,8

30,0 40,0 50,0 60,0 70,0 80,0 90,0 Liquidity 31.12.19 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Liquidity 31.03.20

slide-17
SLIDE 17

Sto Stock ck an and Dividen d Dividend in E in EUR/St UR/Stoc

  • ck

17 Slides only for illustration – the spoken word shall be binding

0,60 0,60 0,60 0,66 0,8 1,2 1,7

20 40 60 80 100 120 140 160 180 200 0,50 0,70 0,90 1,10 1,30 1,50 1,70 2014 2015 2016 2017 2018 2019 2020 Dividend in EUR/Share EUR/Aktie

slide-18
SLIDE 18

18

Cor Coron

  • na Upd

a Updat ate Lo Look

  • king

ing Ah Ahea ead Exp Expec ecta tation tions s for for 2020 2020

Folie nur zur Illustration – es gilt das gesprochene Wort

slide-19
SLIDE 19

Key Key Elemen Elements ts of

  • f

Guida Guidanc nce 20 2020 20 (EBIT) (EBIT)

Slides only for illustration –the spoken word shall be binding 19

in Mio. EUR

slide-20
SLIDE 20

Exp Expan ansion sion Str Strat ateg egy Galli Gallium um-68 68/ / The Thera rano nost stics ics

Slides only for illustration – the spoken word shall be binding 20

EZAG today

Additional indications Additional Isotopes (e.g. Lu-177) Diagnosis Treatment

slide-21
SLIDE 21

Exp Expan ansion sion Str Strat ateg egy Yt Yttr trium ium-90 90/ / Rad Radioemb ioembolisat

  • lisation

ion

Slides only for illustration – the spoken word shall be binding 21

EZAG today

Customer Base Geographic Expansion Europe ROW including China Boston (US) site Chengdu (PRC) site

SIRTEX Europe

slide-22
SLIDE 22

Sho Short rt/ Medium / Medium Ter Term m Goa Goals ls for for Rad Radioph iophar arma ma Ingr Ingred edient ients

Building Worldwide Supply Chains / Global Network

Status as of March 2020 Lutetium-177

  • Validated technology
  • Value chain has been completed
  • Five reactors qualified

thereof two non-European sites

  • First deliveries to customers

Status as of March 2020 Yttrium-90

  • New production site in

Boston initiated

  • Production site in Chengdu

Chengdu on schedule

  • Numerous alliances in the

pipeline

slide-23
SLIDE 23

Fina Financ ncial ial Calen Calenda dar r / I / IR Con R Conta tact ct

IR Contact Eckert & Ziegler AG Karolin Riehle Investor Relations & PR Robert-Rössle-Str. 10 D-13125 Berlin

  • Tel. +49 30 94 10 84-138

Fax +49 30 94 10 84-112 karolin.riehle@ezag.de www.ezag.de ISIN DE0005659700 Reuters EUZ.DE

23 Folie nur zur Illustration – es gilt das gesprochene Wort

12.05.2020 Quarterly Report I 10.06.2020 Annual General Meeting (virtual) 13.08.2020 Quarterly Report II 10.11.2020 Quarterly Report III

(subject to changes)